

CLAIMS

1. An injectable aqueous composition for veterinary use containing a non-steroidal anti-inflammatory compound in an amount of from about 0.5 to 30% (w/v) together with
5 a physiologically acceptable oxygenated polymeric surfactant in an amount of from about 0.5 to 20% (w/v).
2. An injectable aqueous composition according to Claim 1 wherein the non-steroidal anti-inflammatory compound is selected from the group consisting of carprofen,
10 ibuprofen, ketoprofen, benoxaprofen, naproxen, sulindac, zomepirac, fenclofenac, alcofenac, ibufenac, flunixin and indomethacin.
3. An injectable aqueous composition according to Claim 2 wherein the non-steroidal anti-inflammatory compound is carprofen (6-chloro- α -methyl-carbazole-2-acetic
15 acid) or a physiologically acceptable salt thereof.
4. An injectable aqueous composition according to Claim 3 wherein the carprofen salt is in the form of an arginine salt.
- 20 5. An injectable aqueous composition according to Claim 3 wherein the carprofen salt is in the form of a lysine salt.
6. An injectable aqueous composition according to any one of Claims 1 to 3 wherein the non-steroidal anti-inflammatory is present in an amount of from about 2.5 to 7.5%
25 (w/v).
7. An injectable aqueous composition according to any one of Claims 1 to 3 wherein the non-steroidal anti-inflammatory is present in an amount of from about 2.5 to 5%
(w/v).
30
8. An injectable aqueous composition according to any one of Claims 1-7 comprising arginine in an amount of from about 1 to 20% (w/v).

9. An injectable aqueous composition for veterinary use containing a non-steroidal anti-inflammatory compound, preferably carprofen, in an amount of from at least about 0.25% (w/v) together with a physiologically acceptable oxygenated polymeric surfactant in an amount from about 0.5 to 20% (w/v).

5

10. An injectable aqueous composition according to any one of Claims 1 to 9 wherein the polymeric surfactants are selected from polyoxypropylene/polyoxyethylene block copolymers (poloxamers) or derivatives thereof.

10 11. An injectable aqueous composition according to Claim 10 wherein the poloxamers are present in an amount of from about 2 to 12% (w/v).

12. An injectable aqueous composition according to Claim 10 wherein an organic solvent is present with the poloxamer.

15

13. An injectable aqueous composition according to Claim 12 wherein the organic solvent is present in the range of 0.5 to 20% (w/v).

14. An injectable aqueous composition according to Claims 12 or 13 wherein the poloxamers are present in an amount of from 1% to 12% (w/v).

20

15. An injectable aqueous composition according to Claims 10 to 14 wherein the poloxamer is $\text{HO}(\text{CH}_2\text{CH}_2\text{O})_x(\text{CCH}_3\text{HCH}_2\text{O})_y(\text{CH}_2\text{CH}_2)_z\text{H}$ wherein x is about 75, y is about 30 and z is about 75.

25

16. An injectable aqueous composition for veterinary use containing from about 0.25% to 30% (w/v) of carprofen arginine salt together with a poloxamer in an amount from about 0.5 to 20% (w/v).

30

17. An injectable aqueous composition for veterinary use according to claim 16 comprising arginine in an amount of from 1 to 20% (w/v).

18. An aqueous injectable composition comprising carprofen or a physiologically acceptable salt thereof in an amount of from 0.25% to 30% (w/v), a polymeric species

selected from the group of polyoxypropylene/polyoxyethylene block co-polymers in the amount of from 0.5% to 20% (w/v), a preservative and water sufficient for injection.

19. A method of producing a room-temperature stable injectable aqueous composition
5 for veterinary use comprising bringing together an effective amount of carprofen or a physiologically acceptable salt thereof and a poloxamer, and adding sufficient water for injection.

20. A method according to Claim 19 wherein the poloxamer is
10 $\text{HO}(\text{CH}_2\text{CH}_2\text{O})_x(\text{CCH}_3\text{HCH}_2\text{O})_y(\text{CH}_2\text{CH}_2)_z\text{H}$ wherein x is about 75, y is about 30 and z is about 75.

21. A method of producing an injectable aqueous composition according to Claims 19
or 20 wherein said method further comprises the inclusion of a preservative.

15 22. An injectable aqueous composition for veterinary use according to any one of the Examples 1 to 19 hereinbefore.

23. A method of producing an injectable aqueous composition substantially as
20 described in the Example 1.

24. The use of polyoxypropylene/polyoxyethylene block co-polymers for the manufacture of locally tolerable aqueous injection solutions of non-steroidal compounds.